This is the authors' abstract. We don't add key points for this paper.
Although first-generation antihistamines remain popular for the treatment of seasonal allergic rhinitis, atopic dermatitis, and urticaria in children, second- and third-generation antihistamines hold clear advantages over the first-generation agents, especially for the pediatric patient. The less frequent dosing schedule of the second- and third-generation agents makes administration easier for the parent. With less sedation and lower risk of adverse effects, the safety profile of second- and third-generation agents appears superior to that of first-generation agents. After briefly discussing the use of first-generation antihistamines, the pharmacokinetics, safety, and use of the newer antihistamines loratadine, cetirizine, and fexofenadine in the pediatric patient are reviewed.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Chae et al. (2000) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: